7th septiembre 2023
Comunicados de prensa
Encuentre cualquiera de nuestros más recientes comunicados de prensa, manténgase actualizado con las últimas noticias e infórmese sobre los próximos eventos a los que acudirá Curium.
15th agosto 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th julio 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th julio 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st julio 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st julio 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
23rd mayo 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd mayo 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th marzo 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd marzo 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st diciembre 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th noviembre 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd noviembre 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th noviembre 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th agosto 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th junio 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th mayo 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd mayo 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th abril 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th abril 2022